Unlocking Alzheimer’s Mysteries: How PHGDH Changes the Game Alzheimer’s disease remains one of the most challenging neurodegenerative conditions, particularly in its late-onset form (LOAD), which strikes millions without clear genetic risk factors. Recent rese... Alzheimer's amyloid-beta biomarkers neurodegeneration PHGDH therapeutics transcriptional regulation
FDA Clears First Blood-Based Biomarker Test for Alzheimer's: What It Means for Patients and Providers Diagnosing Alzheimer’s disease could be as simple as a routine blood draw thanks to the FDA’s recent clearance of the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test from Fujirebio. This innova... Alzheimer's biomarkers diagnostics FDA clearance Fujirebio neurodegenerative diseases plasma test